NASDAQ:CHRS Coherus BioSciences - CHRS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.78 +0.35 (+5.44%) (As of 03/31/2023 01:57 PM ET) Add Compare Share Share Today's Range$6.51▼$6.8350-Day Range$5.89▼$9.1852-Week Range$5.58▼$14.11Volume335,167 shsAverage Volume1.13 million shsMarket Capitalization$539.76 millionP/E RatioN/ADividend YieldN/APrice Target$16.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Coherus BioSciences MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside144.4% Upside$16.50 Price TargetShort InterestBearish15.14% of Shares Sold ShortDividend StrengthN/ASustainability-1.08Upright™ Environmental ScoreNews Sentiment0.46Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.45) to $1.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector393rd out of 1,009 stocksBiological Products, Except Diagnostic Industry68th out of 166 stocks 3.4 Analyst's Opinion Consensus RatingCoherus BioSciences has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.50, Coherus BioSciences has a forecasted upside of 144.4% from its current price of $6.75.Amount of Analyst CoverageCoherus BioSciences has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.14% of the outstanding shares of Coherus BioSciences have been sold short.Short Interest Ratio / Days to CoverCoherus BioSciences has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Coherus BioSciences has recently increased by 22.46%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCoherus BioSciences does not currently pay a dividend.Dividend GrowthCoherus BioSciences does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCoherus BioSciences has received a 69.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Pegfilgrastim", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Coherus BioSciences is -1.08. Previous Next 2.5 News and Social Media Coverage News SentimentCoherus BioSciences has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Coherus BioSciences this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for CHRS on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat Follows2 people have added Coherus BioSciences to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coherus BioSciences insiders have not sold or bought any company stock.Percentage Held by Insiders11.91% of the stock of Coherus BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.45% of the stock of Coherus BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Coherus BioSciences are expected to grow in the coming year, from ($0.45) to $1.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus BioSciences is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus BioSciences is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Coherus BioSciences (NASDAQ:CHRS) StockCoherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.Read More Receive CHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CHRS Stock News HeadlinesMarch 30, 2023 | americanbankingnews.comCoherus BioSciences (NASDAQ:CHRS) Rating Increased to Buy at UBS GroupMarch 29, 2023 | msn.comUBS Upgrades Coherus Biosciences (CHRS)March 31, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 29, 2023 | finance.yahoo.com6 analyst picks: Lululemon sparkles | Pro RecapMarch 28, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For March 28, 2023March 27, 2023 | finance.yahoo.comInvestors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 64% over the last three yearsMarch 9, 2023 | bizjournals.comCancer, biosimilar drug maker Coherus shedding more biotech jobsMarch 9, 2023 | msn.comCoherus BioSciences's Return On Capital Employed OverviewMarch 31, 2023 | The Oxford Club (Ad)Unusual Passive Income Investment (Found on a Golf Course)Marc reveals how anyone can get into a similar opportunity for just $5.March 8, 2023 | finance.yahoo.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Call TranscriptMarch 7, 2023 | finance.yahoo.comQ4 2022 Coherus BioSciences Inc Earnings CallMarch 7, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Hold Rating on Coherus Biosciences (CHRS)March 7, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)March 6, 2023 | seekingalpha.comCoherus BioSciences Non-GAAP EPS of -$0.60 beats by $0.09, revenue of $45.4M misses by $2.57MMarch 6, 2023 | finance.yahoo.comFDA Approves UDENYCA® AutoinjectorMarch 6, 2023 | finance.yahoo.comCoherus BioSciences Reports Fourth Quarter and Full Year 2022 ResultsMarch 5, 2023 | markets.businessinsider.comHere's what Wall Street expects from Coherus BioSciences's earningsMarch 3, 2023 | msn.comA Preview Of Coherus BioSciences's EarningsMarch 1, 2023 | finance.yahoo.comCoherus BioSciences to Present at Upcoming Investor Conferences in MarchFebruary 28, 2023 | finance.yahoo.comCoherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023February 17, 2023 | nasdaq.comAlliancebernstein Now Owns 8.00% of Coherus Biosciences (CHRS)February 15, 2023 | tmcnet.comCoherus and Junshi Biosciences Announce Positive Final OverallFebruary 15, 2023 | finance.yahoo.comCoherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal CarcinomaFebruary 13, 2023 | finance.yahoo.comCoherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid ServicesFebruary 10, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Alphatec Holdings (ATEC), Coherus Biosciences (CHRS)January 31, 2023 | seekingalpha.comCoherus BioSciences: Biosimilar Specialist With Approval Shot For Chinese Cancer Drug Looks Like A BuyJanuary 26, 2023 | reuters.comCHRS.O - | Stock Price & Latest News | ReutersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CHRS Company Calendar Last Earnings3/06/2023Today3/31/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHRS CUSIPN/A CIK1512762 Webwww.coherus.com Phone(650) 649-3530FaxN/AEmployees332Year Founded2010Price Target and Rating Average Stock Price Forecast$16.50 High Stock Price Forecast$26.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+156.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-291,750,000.00 Net Margins-138.24% Pretax Margin-138.24% Return on Equity-422.10% Return on Assets-53.75% Debt Debt-to-Equity RatioN/A Current Ratio2.75 Quick Ratio2.47 Sales & Book Value Annual Sales$211.04 million Price / Sales2.43 Cash FlowN/A Price / Cash FlowN/A Book Value($1.77) per share Price / Book-3.63Miscellaneous Outstanding Shares79,610,000Free Float70,128,000Market Cap$511.89 million OptionableOptionable Beta0.92 Social Links Key ExecutivesDenny M. LanfearChairman, President & Chief Executive OfficerMcDavid StilwellChief Financial OfficerRichard L. HameisterChief Technical OfficerRosh DiasChief Medical OfficerBryan McmichaelChief Accounting Officer, Senior VP & ControllerKey CompetitorsAgenusNASDAQ:AGENEditas MedicineNASDAQ:EDITAlectorNASDAQ:ALECiTeos TherapeuticsNASDAQ:ITOSFate TherapeuticsNASDAQ:FATEView All CompetitorsInstitutional OwnershipVoya Investment Management LLCSold 217,011 shares on 2/28/2023Ownership: 0.103%Parallax Volatility Advisers L.P.Sold 15,000 shares on 2/27/2023Ownership: 0.000%Alliancebernstein L.P.Bought 110,697 shares on 2/16/2023Ownership: 7.994%Legal & General Group PlcBought 2,979 shares on 2/15/2023Ownership: 0.203%E Fund Management Co. Ltd.Bought 6,114 shares on 2/15/2023Ownership: 0.032%View All Institutional Transactions CHRS Stock - Frequently Asked Questions Should I buy or sell Coherus BioSciences stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHRS shares. View CHRS analyst ratings or view top-rated stocks. What is Coherus BioSciences' stock price forecast for 2023? 5 analysts have issued 12 month target prices for Coherus BioSciences' shares. Their CHRS share price forecasts range from $11.00 to $26.00. On average, they predict the company's stock price to reach $16.50 in the next year. This suggests a possible upside of 156.6% from the stock's current price. View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts. How have CHRS shares performed in 2023? Coherus BioSciences' stock was trading at $7.92 at the start of the year. Since then, CHRS shares have decreased by 18.8% and is now trading at $6.43. View the best growth stocks for 2023 here. Are investors shorting Coherus BioSciences? Coherus BioSciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 12,050,000 shares, an increase of 22.5% from the February 28th total of 9,840,000 shares. Based on an average daily volume of 1,260,000 shares, the short-interest ratio is presently 9.6 days. View Coherus BioSciences' Short Interest. When is Coherus BioSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our CHRS earnings forecast. How were Coherus BioSciences' earnings last quarter? Coherus BioSciences, Inc. (NASDAQ:CHRS) released its earnings results on Monday, March, 6th. The biotechnology company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.12. The biotechnology company had revenue of $45.35 million for the quarter, compared to the consensus estimate of $45.72 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 422.10% and a negative net margin of 138.24%. During the same period in the prior year, the company earned ($0.60) EPS. What ETFs hold Coherus BioSciences' stock? ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust Innovation Leaders ETF (ILDR), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Strategas Global Policy Opportunities ETF (SAGP) and Syntax Stratified SmallCap ETF (SSLY). What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO? 21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Coherus BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX). What is Coherus BioSciences' stock symbol? Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS." Who are Coherus BioSciences' major shareholders? Coherus BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (7.99%), Aristotle Capital Boston LLC (2.68%), Geode Capital Management LLC (1.62%), Peregrine Capital Management LLC (1.44%), Citigroup Inc. (0.99%) and Morgan Stanley (0.92%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler. View institutional ownership trends. How do I buy shares of Coherus BioSciences? Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Coherus BioSciences' stock price today? One share of CHRS stock can currently be purchased for approximately $6.43. How much money does Coherus BioSciences make? Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $511.89 million and generates $211.04 million in revenue each year. The biotechnology company earns $-291,750,000.00 in net income (profit) each year or ($3.76) on an earnings per share basis. How many employees does Coherus BioSciences have? The company employs 332 workers across the globe. Does Coherus BioSciences have any subsidiaries? The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..Read More How can I contact Coherus BioSciences? Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com. This page (NASDAQ:CHRS) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.